Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults
Annual burden of RSV-LRTD among US adults-especially older adults and those of all ages with underlying medical conditions-is substantial. Preventive measures, such as recently approved RSV vaccines, have the potential to yield important improvements in public and patient health, and to reduce the economic burden of RSV-LRTD from the US healthcare system and societal perspectives.
Authors
- Derek Weycker (ORCID: https://orcid.org/0000-0002-5405-2215)
- Ahuva Averin (ORCID: https://orcid.org/0000-0002-4490-7021)
- Mark Atwood
- Vincenza Snow (ORCID: https://orcid.org/0000-0002-0995-2185)
- Bradford D. Gessner (ORCID: https://orcid.org/0000-0002-6216-7194)
- Alejandro Cané (ORCID: https://orcid.org/0000-0003-0778-6862)
- Elizabeth Begier (ORCID: https://orcid.org/0000-0002-1287-5416)
- Reiko Sato
- Goda Kijauskaite
- Erin Quinn
Institutions
- Pfizer (United States) (US)
- Prevea Health (US)
Publication Details
- Journal
- Vaccine
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1016/j.vaccine.2024.126323
- Citations
- 6
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.32